Agonist Inhibitor Treatment
Agonist Inhibitor Treatment - Related Videos
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
0 Views •
Cited by 6 •
2013
Receptor tyrosine kinases are ectopically expressed in many cancers and have been identified as therapeutic targets in acute leukemia. This manuscript describes an efficient strategy for pre-clinical evaluation of tyrosine kinase inhibitors for the treatment of acute leukemia.
01:23
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
0 Views •
2024
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body. These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
0 Views •
2024
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH). Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
0 Views •
Cited by 10 •
2011
A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor activation.
FAQs
Opposing outcomes arise from how the compound changes target activity. An agonist engages a receptor to trigger its signaling response, whereas an inhibitor lowers activity by preventing receptor interactions, occupying an enzyme active site, or disrupting a downstream pathway. Comparing these responses helps connect target engagement with changes in cellular or physiological behavior.
The location of inhibition helps explain which stage of a biological response is being altered. Blocking receptor interactions affects signaling at the target, occupying an enzyme active site directly limits enzyme activity, and disrupting a downstream pathway changes events after the initial signal. This distinction supports more precise interpretation of biochemical mechanisms.
Agonist inhibitor treatment is selected according to the desired biological response. Activating a receptor may be appropriate when increased signaling is needed, while suppressing a receptor, enzyme, or downstream pathway may be preferable when reduced activity is the goal. Selectivity and measurable biochemical effects also guide the design of a targeted treatment.
These compounds can be used to examine how molecular targets influence metabolism, signal transduction, and gene expression. An agonist or inhibitor changes a defined point in one of these processes, allowing researchers to relate target activity to a cellular or physiological response. This makes the treatment useful for testing biochemical pathway relationships.
A study generally begins by choosing a biological target and deciding whether activation or suppression is required. The selected compound is then applied in a controlled manner, and the resulting cellular, physiological, or biochemical response is measured. Interpreting that change links the treatment to target activity and helps evaluate whether the intended response occurred.
Researchers use this approach to clarify molecular mechanisms, investigate disease-related biology, and support drug development. By selectively modifying target activity, they can examine pathway behavior and assess whether a controlled biochemical change produces a relevant cellular or physiological outcome. The same strategy also contributes to designing targeted therapies with improved selectivity.
Treatment studies can reveal whether changing a target produces a measurable biochemical effect and how that change relates to broader cellular or physiological responses. Results may help distinguish the roles of receptors, enzymes, and downstream pathways in metabolism, signaling, or gene expression. These findings support mechanism analysis and evaluation of therapeutic strategies.